Ocular dryness – the new Klondike for pharmaceutical companies
Monday, June 24 2013 | 00 h 00 min | News
The firm GlobalData predicts that the market value of drugs for dry eye syndrome will triple over the next 10 years.
According to GlobalData, this growth will be fueled by the condition’s increasing prevalence, the arrival of new drugs, and the marketing of existing drugs in new territories. The firm gives the examples of Restasis (Allergan), very popular in the U.S., which will be launched in Europe by 2014, and Diquas (Santen Pharmaceuticals), available in Japan and Korea, which will soon be launched in China. The market could also see the arrival of new types of drugs, different from the current eye drops.
Drug sales in the U.S. presently account for 63% of the market share. GlobalData predicts that this percentage will drop to 47% in 2022, while the EU’s market shares will grow from 19% to 41%. The firm estimates that sales across the U.S., France, Germany, Italy, Spain, UK, Japan, China, and India will grow from $1.6 billion in 2012 to $5.5 billion in 2022, at an average annual growth rate of 12.8%.
